Senseonics Holdings, Inc. (SENS)
NASDAQ: SENS · Real-Time Price · USD
6.11
-0.76 (-11.14%)
At close: Mar 5, 2026, 4:00 PM EST
6.11
0.00 (0.08%)
After-hours: Mar 5, 2026, 7:53 PM EST
Senseonics Holdings Revenue
In the year 2025, Senseonics Holdings had annual revenue of $35.26M with 56.89% growth. Senseonics Holdings had revenue of $14.26M in the quarter ending December 31, 2025, with 71.82% growth.
Revenue (ttm)
$35.26M
Revenue Growth
+56.89%
P/S Ratio
7.07
Revenue / Employee
$301,342
Employees
117
Market Cap
249.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.26M | 12.79M | 56.89% |
| Dec 31, 2024 | 22.47M | 82.00K | 0.37% |
| Dec 31, 2023 | 22.39M | 6.00M | 36.62% |
| Dec 31, 2022 | 16.39M | 2.71M | 19.85% |
| Dec 31, 2021 | 13.68M | 8.73M | 176.32% |
| Dec 31, 2020 | 4.95M | -16.35M | -76.77% |
| Dec 31, 2019 | 21.30M | 2.39M | 12.63% |
| Dec 31, 2018 | 18.91M | 12.54M | 196.77% |
| Dec 31, 2017 | 6.37M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Quanterix | 138.90M |
| Delcath Systems | 85.23M |
| Sight Sciences | 77.36M |
| Electromed | 68.86M |
| CVRx, Inc. | 56.65M |
| 908 Devices | 56.20M |
| TriSalus Life Sciences | 45.15M |
| SANUWAVE Health | 41.28M |
SENS News
- 3 days ago - Senseonics Holdings, Inc. (SENS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 14 days ago - Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365 - GlobeNewsWire
- 14 days ago - Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365 - GlobeNewsWire
- 5 weeks ago - Senseonics Receives European Approval for Eversense 365, World's Longest-lasting Continuous Glucose Monitor - GlobeNewsWire
- 2 months ago - Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System - GlobeNewsWire
- 2 months ago - Senseonics: Eversense 365 Is A Game Changer For The CGM Industry - Seeking Alpha
- 4 months ago - Senseonics Holdings, Inc. (SENS) Q3 2025 Earnings Call Transcript - Seeking Alpha